Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented…

Continue ReadingMobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart…

Continue ReadingStage 1 findings support continued pivotal phase evaluation of gotistobart

Study reinforces generalizability of perioperative azithromycin for unplanned cesarean deliveries

Infection can develop in up to 10-20% of patients after a Cesarean delivery, and the risk nearly doubles for those who have an unplanned cesarean delivery, such as those performed…

Continue ReadingStudy reinforces generalizability of perioperative azithromycin for unplanned cesarean deliveries

New IASLC grading system improves risk stratification in resected lung squamous cell carcinoma

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of…

Continue ReadingNew IASLC grading system improves risk stratification in resected lung squamous cell carcinoma

Study reveals characteristics and outcomes in NSCLC patients harboring class II and III BRAF alterations

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse…

Continue ReadingStudy reveals characteristics and outcomes in NSCLC patients harboring class II and III BRAF alterations

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable…

Continue ReadingFinal results from PAPILLON trial confirm long-term survival in a subset of lung cancer